No Summary

Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial - STAT

Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial

Sources

---

Paywall and unreadable sources

• Barron's
  Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 47% Drop.
• STAT
  Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial
• The Clinical Trial Vanguard
  Ultragenyx’s apazunersen fails Phase 3 primary endpoint in Angelman syndrome
• marketscreener.com
  Evercore ISI Downgrades Ultragenyx Pharmaceutical to In Line From Outperform, Adjusts Price Target to $16 From $34
• pharmaphorum
  Ultragenyx to slash costs after Angelman therapy failure